Abstract
The study investigated the economic burden of vaso-occlusive crisis (VOC) among sickle cell disease (SCD) patients, through assessment of overall utilization and costs and costs per VOC episode (regarding the number of VOC episodes and health care setting, respectively). Using the Medicaid Analytic Extracts database, the first SCD-related diagnosis claim (index claim) between June 1, 2009-December 31, 2012 was identified among eligible adults. Patients were required to have continuous medical and pharmacy benefits for 6 months pre- and 12 months post-index. Discrete VOC claims identified within a 3-day gap were combined as a single VOC episode. Annual all-cause and SCD-related medical resources and costs were identified and stratified by number of VOC episodes during the 1-year follow-up period. Health care costs per VOC episode were also examined, stratified by care setting. Enrollees included 8521 eligible patients with a mean age of 32.88 years (SD=12.21). Of these, 66.5% had a Charlson Comorbidity index (CCI) score of 0 (no comorbidities) and 67.3% were female. The average total medical costs were US$34 136 (median=US$12 691) annually, and SCD accounted for 60% of the total costs (mean=US$20 206, median=US$1204). Patients w...Continue Reading
References
Apr 12, 1990·The New England Journal of Medicine·G P RodgersA W Nienhuis
Apr 1, 1995·Pain·B S ShapiroM T Orne
Nov 27, 1997·The New England Journal of Medicine·A SoloveyR P Hebbel
Mar 5, 2003·British Journal of Health Psychology·Kofi A. AnieDavid H. Bevan
Nov 30, 2005·American Journal of Hematology·Sadhna M ShankarMarie R Griffin
Aug 23, 2006·American Journal of Hematology·Sophie LanzkronGeorge J Dover
Jan 16, 2008·Annals of Internal Medicine·Wally R SmithSusan D Roseff
Oct 8, 2008·Pediatric Blood & Cancer·Jean L RaphaelAngelo P Giardino
Apr 10, 2009·American Journal of Hematology·Teresa L KaufAbraham G Hartzema
May 6, 2009·American Journal of Hematology·Samir K Ballas
Jun 6, 2009·Pediatric Blood & Cancer·Mercy MvunduraScott D Grosse
Jul 18, 2009·American Journal of Hematology·Gregory J KatoMark T Gladwin
Apr 2, 2010·American Journal of Preventive Medicine·Djesika D AmendahScott D Grosse
Dec 7, 2010·Lancet·David C ReesMark T Gladwin
Jan 18, 2011·Hematology·Wally R Smith, Marshall Scherer
Sep 6, 2012·Journal of Medical Economics·Edward P ArmstrongSamir K Ballas
Jan 22, 2013·Pediatric Blood & Cancer·Morey A BlinderMei Sheng Duh
Oct 8, 2013·Blood Reviews·Julie Kanter, Rebecca Kruse-Jarres
Dec 10, 2013·Hematology·Stella T Chou
Jan 1, 2013·Medicare & Medicaid Research Review·Vivian L H Byrd, Allison Hedley Dodd
Dec 8, 2015·Hematology·Sophie Lanzkron, Carlton Haywood
Jan 14, 2016·Blood·Dachuan ZhangPaul S Frenette
Feb 3, 2016·Chest·Enrico M Novelli, Mark T Gladwin
Mar 5, 2016·Experimental Biology and Medicine·Alawi Habara, Martin H Steinberg
Oct 9, 2018·American Journal of Hematology·Abdullah KutlarKenneth I Ataga
Jun 15, 2019·The New England Journal of Medicine·Elliott VichinskyUNKNOWN HOPE Trial Investigators
Mar 26, 2020·Blood Cells, Molecules & Diseases·Yuncheng ManUmut A Gurkan